|
|
Volumn 29, Issue 10, 2011, Pages 853-855
|
|
Engineered T-cell therapy shows efficacy in blood cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IMMUNOGLOBULIN RECEPTOR;
ANIMAL;
BLOOD DISEASE;
CLINICAL TRIAL (TOPIC);
DRUG INDUSTRY;
ECONOMICS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
METHODOLOGY;
MOUSE;
NOTE;
PERSONALIZED MEDICINE;
REMISSION;
T LYMPHOCYTE;
TREATMENT OUTCOME;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HEMATOLOGIC NEOPLASMS;
HUMANS;
IMMUNOTHERAPY;
INDIVIDUALIZED MEDICINE;
MICE;
RECEPTORS, IMMUNOLOGIC;
REMISSION INDUCTION;
T-LYMPHOCYTES;
TREATMENT OUTCOME;
|
|
EID: 84856374598
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1011-853 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
